Kezar Life Sciences to Participate in Fireside Chat During the Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Kezar Life Sciences announced that its executive team will participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 1:30 PM EDT. The event will be accessible via live webcast through the company's website, with an archived replay available for 90 days post-conference. Kezar focuses on innovative therapies for autoimmune diseases and cancer, with candidates like KZR-616 and KZR-261 in development.

SOUTH SAN FRANCISCO, May 28, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced members of its executive team will participate in a Fireside Chat during the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 1:30pm EDT.  

The presentation will be webcast live and may be accessed at the “Events & Presentations” section of the Company’s website at http://investors.kezarlifesciences.com/events. Kezar Life Sciences will maintain an archived replay of the webcast on its website for 90 days after the conference.

About Kezar Life Sciences

Based in South San Francisco, Kezar Life Sciences is a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. Kezar is translating its innovative research on the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class selective immunoproteasome inhibitor, is being evaluated in severe and underserved autoimmune diseases.  Additionally, KZR-261, the first clinical candidate for the treatment of cancer from Kezar’s protein secretion program, is undergoing IND-enabling activities. For more information, visit www.kezarlifesciences.com.      

CONTACT:
Celia Economides
IR@kezarbio.com  

FAQ

When is Kezar Life Sciences participating in the Jefferies Virtual Healthcare Conference?

Kezar Life Sciences will participate in the Jefferies Virtual Healthcare Conference on June 4, 2020, at 1:30 PM EDT.

How can I access the Kezar Life Sciences presentation at the conference?

The presentation will be available via live webcast on Kezar Life Sciences' website in the 'Events & Presentations' section.

What are the therapeutic focuses of Kezar Life Sciences?

Kezar Life Sciences focuses on developing novel small molecule therapeutics for autoimmune diseases and cancer.

What is KZR-616 and its purpose in the company's research?

KZR-616 is a first-in-class selective immunoproteasome inhibitor being evaluated for severe and underserved autoimmune diseases.

What is KZR-261 and its current status?

KZR-261 is the first clinical candidate from Kezar's protein secretion program, currently undergoing IND-enabling activities.